Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology · Primary Myelofibrosis

What Does Triple-Negative Myelofibrosis Mean for Your Care?

At a Glance

Triple-negative myelofibrosis means testing did not find JAK2, CALR, or MPL mutations; it does not rule out the disease. It may signal higher risk on average, but prognosis and treatment depend on biopsy findings, blood counts, other mutations, symptoms, and overall health.

In this answer

3 sections

01

Confirming the Diagnosis

02

What Triple-Negative Means for Your Prognosis

03

Treatment Approaches

A “triple-negative” result means that the specific test performed found no detectable canonical (standard) JAK2, CALR, or MPL driver mutations [1]. A driver mutation is a genetic change that tells cells to grow out of control.

Hearing this term can be frightening, but it does not mean you don’t have myelofibrosis [2][3]. Because basic tests might lack the sensitivity to detect very low levels of a mutation, and because not everyone has one of these three common mutations, your care team will look closer at your diagnosis, order broader testing, and carefully evaluate your overall health to guide your prognosis and treatment [4].

Confirming the Diagnosis

When you test negative for the “big three” driver mutations, it is critical to confirm that the scarring in your bone marrow is truly primary myelofibrosis. Diagnosing myelofibrosis is an integrated decision that does not rely on any single test or symptom.

  • Expert review of the bone marrow biopsy: Diagnosis depends heavily on morphology (how the bone marrow cells look under a microscope) and the specific grade of scarring (fibrosis) [5][6].
  • Broader genetic testing: Next-Generation Sequencing (NGS) is a broad genetic test that can look deeper for unusual JAK2 or MPL variants, or other mutations that help support the diagnosis [7][8][9]. While NGS helps, finding a mutation does not prove you have myelofibrosis on its own, and a negative panel does not rule it out [3].
  • Ruling out other causes: Your care team must ensure the fibrosis isn’t caused by something else, such as autoimmune conditions, or secondary myelofibrosis arising from a prior blood disorder like polycythemia vera or essential thrombocythemia [2][3].

What Triple-Negative Means for Your Prognosis

In large population studies, having triple-negative primary myelofibrosis is generally considered an adverse (less favorable) feature compared to having a CALR mutation. It is associated with a higher risk of the disease transforming into acute myeloid leukemia (AML) and shorter overall survival in some studies [10][11][12].

However, this association is based on population averages; it does not predict what will happen to you individually [13]. Your prognosis is not defined by the triple-negative label alone.

To estimate risk, hematologists use formal scoring systems (such as DIPSS-plus, MIPSS70+ version 2, or GIPSS) [14][4][15]. These models differ—some focus more on clinical signs, while others focus heavily on genetics—but your doctor will choose the one most appropriate for you. They combine many factors to estimate population-level risk, including:

  • Other genetic mutations and chromosomes: High-risk mutations (like ASXL1 or SRSF2) and abnormal chromosomes (found via cytogenetics testing) heavily impact prognosis [13][11][15].
  • Blood counts and age: Older age, severe anemia (low red blood cells), low platelets, high white blood cell counts, and the presence of immature cells (circulating blasts) in the blood [14][16].
  • Symptoms: Severe fatigue, night sweats, unexplained fever, or weight loss (called constitutional symptoms), as well as needing blood transfusions [14][4].

Treatment Approaches

Treatment for triple-negative myelofibrosis is highly individualized. It is customized based on your symptoms, blood counts, and formal risk score, rather than your mutation status [15][17].

  • Observation: If you have low-risk disease and no bothersome symptoms, your doctor may recommend “watch and wait.” This involves periodic blood tests, physical exams to check spleen size, and symptom reviews [15].
  • Symptom Management (JAK Inhibitors): Medications like ruxolitinib, pacritinib, momelotinib, and fedratinib can help shrink an enlarged spleen and relieve severe symptoms [18][19][20]. These drugs can improve quality of life even if you do not have a JAK2 mutation, but they are not a cure. The choice of drug depends on your specific situation (for example, pacritinib may be used if platelets are very low, while momelotinib may be favored for severe anemia) [15][20]. Note: JAK inhibitors require careful monitoring for infections and low blood counts, and should never be stopped abruptly without your doctor’s guidance.
  • Supportive Care and Clinical Trials: Your plan may include treatments focused solely on managing anemia (such as certain medications or scheduled blood transfusions) [21][22]. You may also consider clinical trials, which offer access to new, experimental therapies.
  • Stem Cell Transplant: An allogeneic stem cell transplant replaces your diseased bone marrow with healthy cells from a donor. It is the only established treatment with the potential to cure myelofibrosis [23]. However, it is an intensive procedure carrying severe risks, including life-threatening infections, organ damage, graft-versus-host disease (GVHD), and treatment-related mortality [23][24]. Because triple-negative disease can carry a higher risk, a consultation to weigh the individualized risks and benefits of a transplant may be appropriate earlier, especially for patients with intermediate or high-risk disease who are otherwise medically fit [24].

Common questions in this guide

What does triple-negative myelofibrosis mean?
It means testing did not detect mutations in the three most common myelofibrosis-related genes: JAK2, CALR, or MPL. This result does not rule out myelofibrosis, because some mutations may be present at very low levels or may involve other genes.
Does a triple-negative result mean myelofibrosis was diagnosed incorrectly?
No. The diagnosis is based on the complete picture, including a bone marrow biopsy, the amount and pattern of scarring, blood findings, and other clinical information. Doctors may use broader genetic testing and check for other conditions that can cause bone marrow scarring.
Does triple-negative myelofibrosis always mean a poor prognosis?
Not always. Studies show that triple-negative primary myelofibrosis can have less favorable outcomes on average than disease with a CALR mutation, but the result cannot predict one person's future by itself. Your age, blood counts, symptoms, chromosome results, other mutations, and formal risk score also matter.
How do doctors estimate the prognosis of triple-negative myelofibrosis?
Hematologists use risk models that combine several findings rather than relying on the mutation result alone. These may include blood counts, age, symptoms, transfusion needs, chromosome changes, other gene mutations, and immature blood cells.
Can JAK inhibitor medicines work if I do not have a JAK2 mutation?
Yes. Medicines such as ruxolitinib, pacritinib, momelotinib, and fedratinib may reduce spleen enlargement and improve symptoms even when JAK2 is not detected. They do not cure myelofibrosis and require monitoring for infections and low blood counts.
When might a stem cell transplant be considered for triple-negative myelofibrosis?
An allogeneic stem cell transplant is the only established treatment with the potential to cure myelofibrosis, but it can cause life-threatening complications. A transplant consultation may be considered earlier for medically fit people with intermediate- or high-risk disease so they can weigh the possible benefits and risks.

Related questions

How Do Doctors Choose a JAK Inhibitor for Myelofibrosis? Can My Myelofibrosis Risk Score Change Over Time? Does Prefibrotic Myelofibrosis Need Treatment or Monitoring? How to Manage Fullness and Weight Loss in Myelofibrosis? How Common Is Myelofibrosis and Who Is at Risk? Explained
Show more
How Is Accelerated or Blast-Phase Myelofibrosis Diagnosed? How Are Low Platelets and Bleeding Treated in Myelofibrosis? How Is Myelofibrosis-Related Anemia Treated? Key Options How Is Post-PV/ET Myelofibrosis Different From Primary MF? How Often Are Myelofibrosis Monitoring Visits Needed? Is Myelofibrosis Hereditary? Should Relatives Be Tested? What Are My Treatment Options if a JAK Inhibitor Fails? Positive JAK2, CALR or MPL Post-Transplant: What Now? What Do White Blood Cell Counts Mean in Myelofibrosis? Can I Exercise Safely With Myelofibrosis and Splenomegaly? What Happens During a Bone Marrow Biopsy for Myelofibrosis? What If I Need Frequent Transfusions for Myelofibrosis? What Blood Tests Are Needed for JAK Inhibitors in Myelofibrosis? When Should Myelofibrosis Tests Be Repeated After Changes?

Get notified when new evidence is published on myelofibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Mutational profiling in myelofibrosis: implications for management.

    Bose P, Verstovsek S

    International journal of hematology 2020; (111(2)):192-199 doi:10.1007/s12185-019-02758-z.

    PMID: 31630335
  2. 2

    Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis.

    Tsutsui M, Yasuda H, Ota Y, Komatsu N

    Case reports in oncology 2019; (12(3)):834-837 doi:10.1159/000504129.

    PMID: 31762757
  3. 3

    How I Diagnose Primary Myelofibrosis.

    Prakash S, Orazi A

    American journal of clinical pathology 2022; (157(4)):518-530 doi:10.1093/ajcp/aqac016.

    PMID: 35238345
  4. 4

    Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

    Verma T, Papadantonakis N, Peker Barclift D, Zhang L

    Cancers 2024; (16(3)) doi:10.3390/cancers16030514.

    PMID: 38339265
  5. 5

    Update from the latest WHO classification of MPNs: a user's manual.

    Passamonti F, Maffioli M

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

    PMID: 27913526
  6. 6

    Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

    Rumi E, Cazzola M

    Blood 2017; (129(6)):680-692 doi:10.1182/blood-2016-10-695957.

    PMID: 28028026
  7. 7

    Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.

    Frawley T, O'Brien CP, Conneally E, et al.

    Genetic testing and molecular biomarkers 2018; (22(2)):98-103 doi:10.1089/gtmb.2017.0203.

    PMID: 29323541
  8. 8

    Non-MPL-W515K/L mutations in myeloproliferative neoplasms: Insights from two case reports and a review of the literature.

    Tønne Nesse AS, Gjelberg HK, Sandnes M, et al.

    Expert review of hematology 2025; (18(10)):855-865 doi:10.1080/17474086.2025.2527345.

    PMID: 40579775
  9. 9

    Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing.

    Maddali M, Venkatraman A, Kulkarni UP, et al.

    Annals of hematology 2022; (101(9)):1987-2000 doi:10.1007/s00277-022-04920-w.

    PMID: 35840818
  10. 10

    JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.

    Kim BH, Cho YU, Bae MH, et al.

    Journal of Korean medical science 2015; (30(7)):882-8 doi:10.3346/jkms.2015.30.7.882.

    PMID: 26130950
  11. 11

    Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.

    Alshemmari SH, Rajan R, Emadi A

    Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2016; (25(6)):501-509 doi:10.1159/000450956.

    PMID: 27756071
  12. 12

    Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.

    Yogarajah M, Tefferi A

    Mayo Clinic proceedings 2017; (92(7)):1118-1128 doi:10.1016/j.mayocp.2017.05.010.

    PMID: 28688466
  13. 13

    Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

    Tefferi A, Nicolosi M, Mudireddy M, et al.

    American journal of hematology 2018; (93(3)):348-355 doi:10.1002/ajh.24978.

    PMID: 29164670
  14. 14

    Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

    Tefferi A

    American journal of hematology 2016; (91(12)):1262-1271 doi:10.1002/ajh.24592.

    PMID: 27870387
  15. 15

    Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.

    Tefferi A

    American journal of hematology 2023; (98(5)):801-821 doi:10.1002/ajh.26857.

    PMID: 36680511
  16. 16

    Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients.

    Kim TY, Kwag D, Lee JH, et al.

    Cancers 2022; (14(18)) doi:10.3390/cancers14184485.

    PMID: 36139644
  17. 17

    Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.

    Gill H, Leung GMK, Ooi MGM, et al.

    Clinical and experimental medicine 2023; (23(8)):4199-4217 doi:10.1007/s10238-023-01189-9.

    PMID: 37747591
  18. 18

    Myelofibrosis: an update on drug therapy in 2016.

    Bose P, Verstovsek S

    Expert opinion on pharmacotherapy 2016; (17(18)):2375-2389 doi:10.1080/14656566.2016.1252333.

    PMID: 27774820
  19. 19

    [Myelofibrosis: A review].

    Genthon A, Killian M, Mertz P, et al.

    La Revue de medecine interne 2021; (42(2)):101-109 doi:10.1016/j.revmed.2020.08.018.

    PMID: 33243417
  20. 20

    Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

    Griesshammer M, Al-Ali HK, Baerlocher GM, et al.

    International journal of cancer 2026; (159(7)):1642-1662 doi:10.1002/ijc.70596.

    PMID: 42324204
  21. 21

    Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.

    Tefferi A

    American journal of hematology 2018; (93(12)):1551-1560 doi:10.1002/ajh.25230.

    PMID: 30039550
  22. 22

    Momelotinib - a promising advancement in the management of myelofibrosis in adults with anemia.

    Furqan M, Oduoye MO

    Frontiers in oncology 2024; (14()):1411972 doi:10.3389/fonc.2024.1411972.

    PMID: 38983933
  23. 23

    Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

    Kröger NM, Deeg JH, Olavarria E, et al.

    Leukemia 2015; (29(11)):2126-33 doi:10.1038/leu.2015.233.

    PMID: 26293647
  24. 24

    Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.

    Kröger N, Bacigalupo A, Barbui T, et al.

    The Lancet. Haematology 2024; (11(1)):e62-e74 doi:10.1016/S2352-3026(23)00305-8.

    PMID: 38061384

This page is for informational purposes only and does not constitute medical advice about a triple-negative myelofibrosis result. A hematologist should interpret your diagnosis, risk score, and treatment options with you.